WASHINGTON (dpa-AFX) - Avanir Pharmaceuticals, Inc. (AVNR) reported a second-quarter net loss of $17.0 million or $0.13 per share, wider than the net loss of $14.5 million or $0.12 per share in the same period last year.
On average, 6 analysts polled by Thomson Reuters expected the company to report a loss of $0.12 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenues for the quarter rose to $10.0 million from $1.4 million a year ago. These revenues consists of NUEDEXTA revenue and royalty revenue from Abreva.
Analysts expected revenues of $7.81 million for the quarter.
NUEDEXTA is a FDA-approved treatment for pseudobulbar affect, which can be caused by a variety of neurological diseases and brain injury.
Copyright RTT News/dpa-AFX
© 2012 AFX News
